Looking Beyond Conventional Lipid Biomarkers in Metabolic, Neurological, and Chronic Disease

Ceramides, sphingomyelins, and phospholipids give you diagnostic information the standard lipid panel does not provide in metabolic, neurological, and chronic disease. This webinar teaches you to interpret them in clinical practice, use them to identify metabolic risk in patients who fall within conventional reference ranges, and measure your therapeutic outcomes with objective longitudinal biomarker data.

The session maps the cellular systems these markers represent: membrane composition, mitochondrial and peroxisomal function, methyltransferase activity, and inflammatory resolution. Real patient data demonstrates how each system responds under specific interventions and illustrates why a patient who receives a confirmed diagnosis still carries the biochemical state that preceded it.

Dayan Goodenowe, PhD, ranks in the top one percent of researchers in metabolomics and lipidomics including decades of work mapping biochemical patterns across neurodegenerative disease and cancer.